Elanco Animal Health Inc. — Q2 2020 Form 10-Q
Business context and reporting period. Global animal-health company serving companion- and food-animal markets. This filing covers the quarter and six months ended June 30, 2020; comparisons are with the same 2019 periods. All amounts below are in millions of dollars except per-share data.
Key financial results
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Revenue | $586.3 | $781.6 | $1,244.0 | $1,512.7 |
| Gross profit / margin | $290.4 / 49.5% | $425.6 / 54.5% | $615.4 / 49.5% | $812.9 / 53.8% |
| Net income (loss) | $(53.2) | $35.9 | $(102.3) | $67.4 |
| Diluted EPS | $(0.13) | $0.10 | $(0.25) | $0.18 |
| Operating cash flow | Not separately reported for quarter | $163.6 | $58.2 |
- Q2 revenue fell 25%; first-half revenue fell 18%. Lower volume was the primary driver, with a 2% unfavorable foreign-exchange effect partly offset by 2% higher pricing in both periods.
- Q2 product-category revenue: Companion Animal Disease Prevention $176.3 (down 21%); Companion Animal Therapeutics $78.0 (down 6%); Food Animal Future Protein & Health $157.9 (down 10%); Food Animal Ruminants & Swine $158.2 (down 42%).
- Cost of sales was 50.5% of revenue in the first half versus 46.3% a year earlier. Lower revenue, unfavorable product/geographic mix and fixed-cost under-absorption pressured gross margin, partly offset by manufacturing productivity and pricing.
- Q2 special charges were $119.4, including $111.1 of acquisition transaction/integration costs; first-half special charges were $194.2. R&D and marketing, selling and administrative expenses declined, reflecting cost controls, variable-pay adjustments, delayed spending and reduced in-person activity.
- Other-net income was $47.9 in Q2, principally including a $45.6 pretax gain from an Australia sale-leaseback. The gain helped offset operating pressures but did not prevent a quarterly net loss.
Financial position, liquidity and financing
- At June 30, cash and cash equivalents were $1,391.1; current assets were $3,191.3 and current liabilities $835.4. Current debt was $25.9.
- Total debt was $2,056.3, including $2,000.0 of senior notes and $72.6 of TEU amortizing notes; long-term debt, net of current portion, was $2,030.4. Cash less total debt implies approximately $665.2 of net debt, excluding restricted cash.
- First-half operating cash flow was $163.6; investing cash use was $9.0; financing cash inflow was $903.9. Financing included $1,219.9 of net proceeds from common-stock and tangible-equity-unit issuances, partly offset by debt repayments. Cash, cash equivalents and restricted cash increased $1,056.7 to $1,401.8.
- Management said available cash, operating cash flows and financing arrangements should meet needs for at least the next 12 months. The company estimated annual interest expense of approximately $99 million based on debt outstanding at June 30.
Material changes, outlook and risks
- COVID-19 reduced veterinary visits and demand for some companion-animal products, while food-animal demand was affected by processing-plant closures, producer pressure and lower milk production. Elanco also reduced distributor channel inventory. Management expected demand declines versus prior year, particularly in food animal, to continue through the rest of 2020. No specific full-year revenue or earnings guidance is provided in the supplied filing text.
- Elanco expected to close its $5.3 billion cash plus approximately $2.3 billion stock acquisition of Bayer’s animal-health business in August 2020, subject to closing conditions. Financing was arranged, including a proposed $4.275 billion term loan B and $750 million revolving facility; proceeds were intended to fund the acquisition and related costs. Integration, financing, leverage and realizing expected benefits remain risks.
- The company estimated standalone transition and systems costs of $240–$290 million, net of potential real-estate dispositions and employee-benefit changes; some costs would be capitalized. Q2 and first-half acquisition, integration and stand-up charges increased materially from 2019.
- On July 27, 2020, after quarter-end, Elanco completed the sale of its remaining Osurnia interest for approximately $141.6 million. Capstar and Vecoxan divestitures were expected to close with the Bayer acquisition.
- A shareholder class-action lawsuit filed in May 2020 alleges misleading statements or omissions concerning supply chain, inventory, revenue and projections. Elanco disputes the claims; the outcome could not be predicted, and no material litigation liability was recorded.
- Other risks include further COVID-19 effects on demand, supply, collections and liquidity; generic competition; distributor inventory fluctuations; foreign exchange; product and regulatory risks; and acquisition integration. Management reported disclosure controls were effective as of June 30, 2020.
Important facts for investors to verify
- Whether reported revenue declines reflect temporary channel destocking and pandemic disruption or sustained end-customer weakness; track category trends and distributor inventories.
- Progress and final terms of the Bayer acquisition, including closing, divestitures, debt issuance, leverage, covenant headroom and integration costs.
- Cash generation and working-capital quality, especially receivable collections, inventory levels and the sustainability of operating cash flow.
- Underlying profitability excluding the Australia sale-leaseback gain and elevated acquisition, integration and standalone costs; monitor gross-margin recovery.
- Developments in the shareholder lawsuit and any resulting financial, disclosure or reputational consequences.